Jpmorgan Chase & CO Lyell Immunopharma, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 97,143 shares of LYEL stock, worth $123,371. This represents 0.0% of its overall portfolio holdings.

Number of Shares

97,143

Previous 654,622 85.16%

Holding current value

$123,371

Previous $1.46 Million 90.4%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.3 - $3.01 $724,722 - $1.68 Million	-557,479 Reduced 85.16%	97,143 $140,000
Q1 2024 May 10, 2024	BUY	$1.71 - $3.07 $841,367 - $1.51 Million	492,028 Added 302.61%	654,622 $1.46 Million
Q4 2023 Feb 12, 2024	SELL	$1.39 - $2.35 $127,695 - $215,887	-91,867 Reduced 36.1%	162,594 $315,000
Q3 2023 Nov 14, 2023	BUY	$1.45 - $3.35 $27,674 - $63,938	19,086 Added 8.11%	254,461 $374,000
Q2 2023 Aug 11, 2023	SELL	$1.89 - $3.86 $736,404 - $1.5 Million	-389,632 Reduced 62.34%	235,375 $748,000
Q1 2023 May 18, 2023	BUY	$1.97 - $3.58 $400,638 - $728,064	203,370 Added 48.23%	625,007 $1.48 Million
Q1 2023 May 11, 2023	SELL	$1.97 - $3.58 $296,504 - $538,825	-150,510 Reduced 26.31%	421,637 $995,000
Q4 2022 Feb 13, 2023	BUY	$2.78 - $8.09 $144,990 - $421,933	52,155 Added 10.03%	572,147 $1.99 Million
Q3 2022 Nov 14, 2022	SELL	$5.54 - $8.27 $39,788 - $59,395	-7,182 Reduced 1.36%	519,992 $3.81 Million
Q2 2022 Aug 11, 2022	BUY	$3.68 - $6.8 $32,273 - $59,636	8,770 Added 1.69%	527,174 $3.44 Million
Q1 2022 May 11, 2022	BUY	$5.05 - $7.7 $272,967 - $416,208	54,053 Added 11.64%	518,404 $2.62 Million
Q4 2021 Feb 10, 2022	BUY	$7.13 - $15.19 $871,849 - $1.86 Million	122,279 Added 35.75%	464,351 $3.59 Million
Q3 2021 Nov 12, 2021	BUY	$11.0 - $17.95 $3.76 Million - $6.14 Million	342,072 New	342,072 $5.06 Million

Others Institutions Holding LYEL

# of Institutions

119

Shares Held

145M

Call Options Held

2.6K

Put Options Held

7.5K

View Full List

About Lyell Immunopharma, Inc.

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $315M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

More about LYEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Lyell Immunopharma, Inc. Transaction History